Sagimet Biosciences Inc Series A (SGMT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | |
| Assets | ||||
| Current Assets | ||||
| Cash & Cash Equivalents | 35,021 | 75,840 | 75,139 | 158 |
| Marketable Securities | 78,103 | 75,410 | 19,758 | 32,187 |
| TOTAL | $116,404 | $152,774 | $96,646 | $32,792 |
| Non-Current Assets | ||||
| Investments And Advances | 0 | 7,408 | 0 | 27 |
| Other Non-Current Assets | 78 | 77 | 73 | 212 |
| TOTAL | $78 | $7,485 | $73 | $239 |
| Total Assets | $116,482 | $160,259 | $96,719 | $33,031 |
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts payable and accrued liabilities | 1,309 | 1,425 | 186 | 1,125 |
| Accrued Expenses | 3,714 | 2,951 | 5,403 | 4,021 |
| TOTAL | $5,101 | $4,454 | $5,654 | $5,279 |
| Non-Current Liabilities | ||||
| Other Non-Current Liabilities | 0 | 0 | 0 | 214,702 |
| TOTAL | $N/A | $N/A | $N/A | $214,702 |
| Total Liabilities | $5,101 | $4,454 | $5,654 | $219,981 |
| Shareholders' Equity | ||||
| Shares Outstanding, K | 32,585 | 32,195 | 31,914 | N/A |
| Common Shares | 3 | 3 | 2 | 1 |
| Retained earnings | -346,349 | -295,311 | -249,744 | -221,868 |
| Other shareholders' equity | 120 | 230 | 30 | -84 |
| TOTAL | $111,381 | $155,805 | $91,065 | $-186,950 |
| Total Liabilities And Equity | $116,482 | $160,259 | $96,719 | $33,031 |